Caris Life Sciences Form 4: 99k-Share RSU Grant to CFO Luke Power

Rhea-AI Filing Summary

Caris Life Sciences, Inc. (CAI) – Form 4 insider filing

On 06/23/2025 the company reported that Senior Vice President, Chief Financial Officer and Chief Accounting Officer Luke Thomas Power received an equity award of 99,321 restricted stock units (RSUs) dated 06/18/2025. The RSUs were acquired at no cost (transaction code “A”, price $0) and increase the executive’s direct beneficial ownership of CAI common stock to 99,571 shares.

The filing states that the RSUs “vest in accordance with the applicable grant agreement,” but provides no additional vesting schedule details. No open-market purchases, sales, or derivative security transactions were disclosed in either Table I or Table II.

Because the transaction is a standard compensation grant rather than a market purchase, it does not signal the officer’s view on valuation. However, the size of the award significantly expands the CFO’s equity exposure, aligning management incentives more closely with shareholder interests. Investors may monitor future filings for vesting-related sales or additional equity awards that could affect ownership levels.

Insights

Securities Analyst

TL;DR – Routine RSU grant lifts CFO stake; neutral cash impact, limited valuation signal.

The 99,321-share RSU award granted on 06/18/25 is compensatory, carries no cash cost, and raises Luke Power’s holdings to 99,571 shares. While the enlarged stake marginally tightens alignment, the absence of an open-market buy means the filing offers little insight into management’s assessment of CAI’s current valuation. No derivatives or sales were reported, so there is no immediate dilution or liquidity signal. In isolation the event is governance-rather than valuation-driven and is therefore broadly neutral for investors.

Corporate Governance Expert

TL;DR – Governance-standard equity award; improves incentive alignment but not materially impactful.

The filing documents a straightforward RSU grant to the CFO, a typical component of executive compensation packages. The award substantially enlarges insider ownership, which shareholders often view favorably from an incentive-alignment standpoint. Nonetheless, without disclosure of performance conditions or vesting cadence, investors cannot gauge the rigor of the grant. Absent any market purchases or option exercises, the event has negligible short-term governance or market impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Power Luke Thomas

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		99,321(1)	A	$0	99,571	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

Senior Vice President, Chief Financial Officer, and Chief Accounting Officer

	/s/ J. Russel Denton, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CAI shares did the CFO acquire in the latest Form 4?

He was awarded 99,321 restricted stock units.

What is the transaction date disclosed in the CAI Form 4?

The grant date is 06/18/2025.

What is Luke Thomas Power’s total beneficial ownership after the transaction?

He now directly owns 99,571 common shares.

Was the transaction an open-market purchase or a compensatory award?

It was a compensatory RSU award at $0.

Were any derivative securities reported in this Form 4?

No, Table II shows no derivative transactions.